Antibody drug conjugates are biopharmaceutical compounds comprising a monoclonal antibody joined to a biologically active cytotoxic drug or cytotoxic agent. Unlike traditional chemotherapy, ADCs are designed to directly deliver cell-killing agents specifically to tumor cells while leaving healthy cells alone. This allows ADCs to eradicate cancerous cells while minimizing unwanted side effects in healthy tissues.

The global Antibody Drug Conjugates Market is estimated to be valued at US$ 5.38 Bn in 2023 and is expected to exhibit a CAGR of 14 % over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

Market key trends:
Antibody-drug conjugates are increasingly finding clinical applications in cancer treatment as they allow for targeted delivery of cytotoxic anticancer agents to tumor sites. Ongoing advancements in linker and payload technologies have improved the therapeutic window of ADCs significantly. For instance, recent ADCs employ newer linker technologies that are more stable in circulation but readily release the drug payload upon cellular internalization at the tumor site. This has enhanced tolerability and therapeutic efficacy compared to earlier ADC agents. ADCs also address the global need for more targeted cancer therapies with improved safety profiles. Growing understanding of tumor biology and advances in conjugation techniques are further expanding the reach of ADCs to treat both hematological and solid tumors.

Porter’s Analysis
Threat of new entrants: The market requires high capital investments for RD and manufacturing facilities which acts as a barrier for new players entering the market.
Bargaining power of buyers: The buyers have moderate bargaining power given the increasing prevalence of cancer worldwide resulting in rising demand for antibody drug conjugates.
Bargaining power of suppliers: The suppliers have moderate bargaining power due to the availability of substitutes and presence of multiple antibody drug conjugate manufacturers.
Threat of new substitutes: The threat from substitutes is moderate as biosimilars and targeted cancer therapies pose competition to antibody drug conjugates.
Competitive rivalry: High due to the presence of many large and small players competing on innovations.

SWOT Analysis
Strengths: High efficacy and specificity in targeting tumor cells. Minimal toxicity compared to conventional cancer therapies. Growing prevalence of cancer drives demand.
Weaknesses: High costs associated with RD, clinical trials and production. Complex manufacturing process. Potential side effects.
Opportunities: Pipeline products targeting new indications. Increasing healthcare budgets in emerging nations. Collaborations for proprietary linker-payload technologies.
Threats: Patent expiry of blockbuster drugs. Reimbursement and regulatory hurdles. Safety issues can impact brand image.

Key Takeaways
The global Antibody Drug Conjugates market is expected to witness high growth at a CAGR of 14% over the forecast period of 2023 to 2030. This is attributed to growing cancer prevalence, advancement of bioconjugation technologies and improving healthcare infrastructure in developing nations.

Regionally, North America dominated the market in 2023 with over 40% of the global revenue. Favourable reimbursement policies and presence of major players drive the market in the region. However, Asia Pacific is poised to witness the fastest growth owing to rising healthcare spending, westernization of lifestyle and expansion of key players in the region.

Key players operating in the Antibody Drug Conjugates market are AstraZeneca PLC, Daiichi Sankyo Company, Limited, Novasep, ADC Therapeutics SA, Alentis Therapeutics AG, F. Hoffmann-La Roche, Gilead Sciences, Inc., AbbVie Inc., Biosion USA, Inc., Astellas Pharma Inc., Duality Biologics (Suzhou) Co. Ltd., BioNTech SE, LaNova Medicines Ltd., Bliss Biopharmaceutical, Eisai Co., Ltd., ProfoundBio, Pfizer, Inc., ImmunoGen Inc., Mersana Therapeutics Inc., Sorrento Therapeutics Inc., Oxford BioTherapeutics Ltd, and Takeda Pharmaceutical Company Ltd.